JNJ vs TERN

Johnson & Johnson (JNJ) remains a fundamentally strong, diversified healthcare conglomerate with an impressive market capitalization. While possessing robust financials, wide economic moats, and consistent performance, its sheer size ($579.46B) fundamentally misaligns with the criteria for 10x growth within a 3-5 year timeframe. A 10x return would necessitate a market cap exceeding $5.7 trillion, ...

Score Change Explanation: The drastic score reduction from 70/100 to 10/100 is due to the fundamental change in Terns Pharmaceuticals' investment profile. On March 25, 2026, Merck agreed to acquire TERN for $53/share cash. This acquisition eliminates TERN's independent 10x growth potential, which was the core thesis of the previous analysis. For existing shareholders, the upside is now capped at t...